Designer Psychostimulants in Urine by Liquid Chromatography–Tandem Mass Spectrometry,

Designer psychostimulants are known by recreational drug users to produce a complex array of adrenergic and hallucinogenic effects. Many of these drugs are not targeted during routine toxicology testing and as a consequence, they are rarely reported. The purpose of this study was to develop a procedure for the detection of 15 psychostimulants in urine using liquid chromatography–tandem mass spectrometry (LC‐MS/MS), specifically 2,5‐dimethoxy‐4‐bromophenethylamine (2C‐B), 2,5‐dimethoxy‐4‐chlorophenethylamine (2C‐C), 2,5‐dimethoxy‐4‐methylphenethylamine (2C‐D), 2,5‐dimethoxy‐4‐ethylphenethylamine (2C‐E), 2,5‐dimethoxyphenethylamine (2C‐H), 2,5‐dimethoxy‐4‐iodophenethylamine (2C‐I), 2,5‐dimethoxy‐4‐ethylthiophenethylamine (2C‐T‐2), 2,5‐dimethoxy‐4‐isopropylthiophenethylamine (2C‐T‐4), 2,5‐dimethoxy‐4‐propylthiophenethylamine (2C‐T‐7), 2,5‐dimethoxy‐4‐bromoamphetamine (DOB), 2,5‐dimethoxy‐4‐chloroamphetamine (DOC), 2,5‐dimethoxy‐4‐ethylamphetamine (DOET), 2,5‐dimethoxy‐4‐iodoamphetamine (DOI), 2,5‐dimethoxy‐4‐methylamphetamine (DOM), and 4‐methylthioamphetamine (4‐MTA). Analytical recoveries using solid‐phase extraction were 64–92% and the limit of detection was 0.5 ng/mL for all drugs except 2C‐B (1 ng/mL). The assay was evaluated in terms of analytical recovery, precision, accuracy, linearity, matrix effect, and interferences. The technique allows for the simultaneous detection of 15 psychostimulants at sub‐ng/mL concentrations.